1. Established biopharmaceutical company with a global presence
• Asset-light business model with significant growth potential
• Strong experience in bringing products to market
2. Innovative technology platform Marinosolv® focused on allergy and eye diseases
• Budesolv for allergic rhinitis Phase III study completed
• Tacrosolv for multiple indications prior to Phase II study
• Potential for additional indications through proprietary programs and/or pharma licensing deals
3. Carragelose®: an OTC platform specifically for the treatment of respiratory diseases
• Six products on the market, distributed in more than 40 countries
• Significant growth potential with additional near term (new) products launches in major markets
4. Experienced leadership team backed by high quality boards
• Strong track record in the pharmaceutical industry and science community
• Backed by an internationally renowned Scientific Advisory Board